Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

被引：0
|
作者：
Jürgen Wollenhaupt
Eun-Bong Lee
Jeffrey R. Curtis
Joel Silverfield
Ketti Terry
Koshika Soma
Chris Mojcik
Ryan DeMasi
Sander Strengholt
Kenneth Kwok
Irina Lazariciu
Lisy Wang
Stanley Cohen
机构：
[1] Struenseehaus,Rheumatologie Hamburg
[2] Seoul National University,undefined
[3] University of Alabama at Birmingham,undefined
[4] Healthpoint Medical Group,undefined
[5] Pfizer Inc,undefined
[6] Pfizer Inc,undefined
[7] Pfizer Inc,undefined
[8] Pfizer Inc,undefined
[9] IQVIA Canada,undefined
[10] Metroplex Clinical Research Center and University of Texas Southwestern Medical Center,undefined
来源：
Arthritis Research & Therapy | / 21卷
关键词：
Rheumatoid arthritis; Tofacitinib; Long-term extension;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Safety and Efficacy of Baricitinib through 128 Weeks in an Open-Label, Long-Term Extension Study in Patients with Rheumatoid Arthritis
    Keystone, Ed
    Taylor, Peter
    Genovese, Mark
    Schlichting, Douglas
    de la Torre, Inmaculada
    Beattie, Scott
    Rooney, Terence
    [J]. JOURNAL OF RHEUMATOLOGY, 2015, 42 (07) : 1292 - 1292
  • [32] CLINICAL OUTCOMES OF RHEUMATOID ARTHRITIS PATIENTS RECEIVING TOFACITINIB MONOTHERAPY IN THE OPEN-LABEL LONG-TERM EXTENSION
    Fleischmann, R.
    Wollenhaupt, J.
    Wang, L.
    Maniccia, A.
    Kwok, K.
    Takiya, L.
    van Vollenhoven, R.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 259 - 260
  • [33] Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel)
    Ruediger B. Mueller
    Hendrik Schulze-Koops
    Daniel E. Furst
    Stanley B.  Cohen
    Kenneth Kwok
    Lisy Wang
    Tim Killeen
    Johannes von Kempis
    [J]. Clinical Rheumatology, 2022, 41 : 1045 - 1055
  • [34] Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel)
    Mueller, Ruediger B.
    Schulze-Koops, Hendrik
    Furst, Daniel E.
    Cohen, Stanley B.
    Kwok, Kenneth
    Wang, Lisy
    Killeen, Tim
    von Kempis, Johannes
    [J]. CLINICAL RHEUMATOLOGY, 2022, 41 (04) : 1045 - 1055
  • [35] Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
    Nash, Peter
    Coates, Laura C.
    Kivitz, Alan
    Mease, Philip J.
    Gladman, Dafna D.
    Covarrubias-Cobos, Jose A.
    Fitzgerald, Oliver
    Fleishaker, Dona
    Wang, Cunshan
    Wu, Joseph
    Hsu, Ming-Ann
    Menon, Sujatha
    Fallon, Lara
    Romero, Ana Belen
    Kanik, Keith S.
    [J]. RHEUMATOLOGY AND THERAPY, 2020, 7 (03) : 553 - 580
  • [36] Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
    Peter Nash
    Laura C. Coates
    Alan J. Kivitz
    Philip J. Mease
    Dafna D. Gladman
    José A. Covarrubias-Cobos
    Oliver FitzGerald
    Dona Fleishaker
    Cunshan Wang
    Joseph Wu
    Ming-Ann Hsu
    Sujatha Menon
    Lara Fallon
    Ana Belén Romero
    Keith S. Kanik
    [J]. Rheumatology and Therapy, 2020, 7 : 553 - 580
  • [37] Tofacitinib for the Treatment of Patients with Juvenile Idiopathic Arthritis: An Interim Analysis of Data up to 5.5 Years from an Open-label, Long-term Extension Study
    Brunner, Hermine I.
    Akikusa, Jonathan
    Al-Abadi, Eslam
    Bohnsack, John
    Boteanu, Alina Lucica
    Chedeville, Gaelle
    Cuttica, Ruben
    De La Pena, Wendy
    Jung, Lawrence
    Kasapcopur, Ozgur
    Kobusinska, Katarzyna
    Schulert, Grant
    Neiva, Claudia
    Rivas-Chacon, Rafael
    Rodriguez, Juan Cruz Rizo
    Vazquez-Del Mercado, Monica
    Wagner-Weiner, Linda
    Weiss, Jennifer E.
    Wouters, Carine
    Suehiro, Ricardo M.
    Posner, Holly
    Wouters, Ann
    Kanik, Keith S.
    Luo, Zhen
    Martini, Alberto
    Lovell, Daniel J.
    Ruperto, Nicolino
    [J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [38] Clinical Outcomes for Rheumatoid Arthritis Patients Receiving Tofacitinib Monotherapy in the Open-Label Long-Term Extension over 6 Years
    Fleischmann, Roy
    Yazici, Yusuf
    Wollenhaupt, Juergen
    Wang, Lisy
    Maniccia, Anna
    Kwok, Kenneth
    Takiya, Liza
    van Vollenhoven, Ronald
    [J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [39] Determinants of tofacitinib discontinuation in adult patients with rheumatoid arthritis during long-term extension studies up to 9.5 years
    Curtis, Jeffrey R.
    Wollenhaupt, Jurgen
    Tas, Sander W.
    Chatzidionysiou, Katerina
    Wang, Lisy
    Roberts, Kevin
    Tsekouras, Vassilis
    [J]. RHEUMATOLOGY ADVANCES IN PRACTICE, 2024, 8 (02)
  • [40] LONG-TERM SAFETY AND EFFICACY OF OLOKIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS - RESULT OF AN OPEN-LABEL EXTENSION STUDY, CREDO4
    Feist, E.
    Nasonov, E.
    Luggen, M.
    Fatenejad, S.
    Grishin, S.
    Samsonov, M.
    Fleischmann, R. M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 593 - 593
12345